BETA-TT17 Cancer

A new concept in cancer chemotherapy. An oral, multi-modal drug combining cytotoxic, anti-angiogenic and immuno-oncology functions, the latter delivering the all-important reversal of T cell exhaustion.

BETA-TT17, like all BETA platform drug candidates, acts via the MEK-ERK-AP1 signal transduction/gene transcription pathway resulting in wide-ranging anti-inflammatory and oncolytic functions.

The multi-modal functions of BETA-TT17 comprise

• the same potent anti-inflammatory and anti-angiogenic properties seen with BETA-TT8.

To which is added a potent anti-cancer action:

• a pro-apoptotic action on a wide range of cancer cell types and cancer mutations

To which is added an immune-oncology action based on up-regulation of cJun action:

• down-regulation of expression by T cells of PD-1
• up-regulation of CD69 expression by CD8+ cells.